InflaRx flatlines after skin disease drug flops in midstage trialShares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug Share XInflaRx flatlines after skin disease drug flops in midstage trialhttps://pharmaphorum.com/news/inflarx-flatlines-skin-disease-drug-midstage-trial/
